Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025919 | 0.89 | MAPK14 (0.77) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL2843659 | 0.89 | MAPK14 (0.77) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3522378 | 0.88 | MAPK14 (0.80) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL9906466 | 0.86 | MAPK14 (0.69) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL13167751 | 0.85 | MAPK14 (0.74) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL5322678 | 0.84 | MAPK14 (0.81) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL5322684 | 0.84 | MAPK14 (0.81) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL9906467 | 0.84 | MAPK14 (0.66) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3522500 | 0.83 | MAPK14 (1.00) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3524735 | 0.83 | MAPK14 (1.00) | MAPK14MAPK11ROCK2MAPK12STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198276-B2 | Kinase inhibitor compounds | XCOVERY HOLDING COMPANY LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198276-B2 | Kinase inhibitor compounds | XCOVERY HOLDING COMPANY LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | COMPASS HORIZON FUNDING COMPANY LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | COMPASS HORIZON FUNDING COMPANY LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008153942-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K9, MAP3K1, MAP3K8 | MAPK14 183/4885MAPK11 413/4885ROCK2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.